Oral Gonadotropin-Releasing Hormone Antagonists in the Treatment of Uterine Myomas: A Systematic Review and Network Meta-analysis of Efficacy Parameters and Adverse Effects

Telek, Savci Bekir
Gurbuz, Zeynep
Kalafat, Erkan
Ata, Baris
© 2022Objective: The aim of this systematic review is to gather and synthesize evidence regarding the use of oral gonadotrophin-releasing hormone (GnRH) antagonist for the treatment of bleeding associated with uterine myomas. Data Sources: Web of Science, and MEDLINE databases were searched electronically on March 5, 2021, using combinations of the relevant Medical Subject Headings terms and keywords. The search was restricted to the English language and to human studies. Methods of Study Selection: Only randomized controlled trials involving patients with heavy menstrual bleeding associated with uterine myomas treated with different doses of oral nonpeptide GnRH antagonists with or without add-back therapy were included. Studies comparing oral nonpeptide GnRH antagonists with treatments other than placebo were also excluded. Tabulation, Integration, and Results: A total of 5 randomized trials including 2463 women were included in the analyses. Included studies were found to be at low risk of bias. When treatments were compared against placebo, the top 3 treatments for bleeding suppression were elagolix 600 mg, 400 mg, and 200 mg without add-back. Elagolix 600 mg without add-back therapy had a significantly higher risk of amenorrhea than lower doses of elagolix with and without add-back and relugolix as well. Uterine volume changes were more pronounced in therapies without add-back. All treatments were associated with significantly improved quality of life scores, both for myoma symptom–related and overall health-related scores. With the exception of relugolix with high-dose add-back, all treatments significantly increased low-density lipoprotein (LDL) levels. Again, all treatment modalities except for elagolix 200 mg without add-back significantly increased LDL-to-HDL ratio. The increase was highest for treatment without add-back therapy. Conclusion: Oral GnRH antagonists seem to be effective for myoma-associated bleeding and for improving quality of life. The safety profile is acceptable for short-term use, but lipid metabolism is affected.
Journal of Minimally Invasive Gynecology


Treatment of implant-related methicillin-resistant Staphylococcus aureus osteomyelitis with vancomycin-loaded VK100 silicone cement: An experimental study in rats
Neyisci, Cagri; Erdem, Yusuf; Bilekli, Ahmet Burak; Demiralp, Bahtiyar; Kose, Ozkan; Bek, Dogan; Korkusuz, Feza; Kankilic, Berna (SAGE Publications, 2018-1)
Introduction: The purpose of this present study is to investigate the efficacy of vancomycin-loaded VK100 silicone cement drug delivery system in the treatment of implant-related methicillin-resistant Staphylococcus aureus (MRSA) osteomyelitis in rats. Materials and Methods: Thirty-six adult (18-20 weeks old) female Sprague-Dawley rats were included in the study. All rats underwent experimental osteomyelitis surgery via injecting 100 mu L bacterial suspension of MRSA into the medullary canal. After a 2-week...
Stratum corneum lipid liposome-encapsulated panomycocin: preparation, characterization, and the determination of antimycotic efficacy against Candida spp. isolated from patients with vulvovaginitis in an in vitro human vaginal epithelium tissue model
İzgü, Kadri Fatih; Tosun, Kubra; Izgu, Demet (2017-01-01)
In this study, a liposomal lyophilized powder formulation of panomycocin was developed for therapeutic purposes against vulvovaginal candidiasis which affects 80% of women worldwide. Panomycocin is a potent antimycotic protein secreted by the yeast Wickerhamomyces anomalus NCYC 434. This study involved the preparation of panomycocin-loaded stratum corneum lipid liposomes (SCLLs), characterization of the SCLLs, and determination of antimycotic efficacy of the formulation against Candida albicans and Candida ...
Morphine biotransformation by microbial phenol oxidases
Erdural Korkmaz, Beril; Bakır, Ufuk; Department of Chemical Engineering (2006)
The objective of this study is to perform morphine biotransformation by using phenol oxidases. Syctalidium thermophilum, Thermomyces lanuginosus and Phanerochaete chrysosporium cells and culture fluid were used as microbial intracellular and extracellular phenol oxidases. Besides the phenol oxidases produced in laboratory, commercial pure phenol oxidases, A. bisporus tyrosinase and laccase, T. versicolor laccase and horseradish peroxidase, were also used in the morphine biotransformation reactions. Morphine...
Application of enzyme/zeolite sensor for urea analysis in serum
Soldatkin, O. O.; Kucherenko, I. S.; Marchenko, S. V.; Kasap, B. Ozansoy; Akata Kurç, Burcu; Soldatkin, A. P.; Dzyadevych, S. V. (2014-09-01)
Urea biosensor based on zeolite-adsorbed urease was applied for analysis of blood serum samples. It should be noted, that this biosensor has a number of advantages, such as simple and fast performance, the absence of toxic compounds during biosensor preparation, high reproducibility and repeatability (RSD = 9% and 4%, respectively). The linear range of urea determination by using the biosensor was 0.003-0.75 mM, and the limit of urea detection was 3 mu M. The method of standard addition was used for analysi...
Tamoxifen Increases Membrane Fluidity at High Concentrations
Severcan, Feride; Kazanci, Nadide; Zorlu, Faruk (Portland Press Ltd., 2000-6-1)
There are contradictory results in the literature relating to the effect of tamoxifen on membrane fluidity. The present work investigates the effect of tamoxifen on membrane dynamics to find out whether the concentration of tamoxifen can be one of the factors in this discrepancy. Turbidity (absorbance at 440 nm) and Fourier transform infrared spectroscopic studies reveal that tamoxifen causes opposite effects on membrane fluidity at low (1 mol.%) and high (30 mol.%) tamoxifen concentrations. Low tamoxifen c...
Citation Formats
S. B. Telek, Z. Gurbuz, E. Kalafat, and B. Ata, “Oral Gonadotropin-Releasing Hormone Antagonists in the Treatment of Uterine Myomas: A Systematic Review and Network Meta-analysis of Efficacy Parameters and Adverse Effects,” Journal of Minimally Invasive Gynecology, vol. 29, no. 5, pp. 613–625, 2022, Accessed: 00, 2022. [Online]. Available: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85123004255&origin=inward.